Optimal selection of individuals for BRCA mutation testing: A comparison of available methods

Journal of Clinical Oncology

Volumn 24, Issue 4, 2006, Pages 707-715

  James, Paul A ^a   Doherty, Rebecca ^a   Harris, Marion ^a   Mukesh, Bickol N ^a   Milner, Alvin ^a   Young, Mary Anne ^a   Scott, Clare ^a  

^a MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ACCURACY; ADOLESCENT; ADULT; AGED; ARTICLE; BAYES THEOREM; BREAST CANCER; CANCER GRADING; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC SCREENING; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; METHODOLOGY; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; ROC CURVE; SCHOOL CHILD; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; BREAST TUMOR; COMPARATIVE STUDY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MUTATION; OVARY TUMOR; PEDIGREE; RISK FACTOR; STANDARD; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; PATIENT SELECTION; PEDIGREE; RISK FACTORS; ROC CURVE;

EID: 33644838384     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.01.9737     Document Type: Article

References (30)

1. Claus EB, Schildkraut JM, Thompson WD, et al: The genetic attributable risk of breast and ovarian cancer. Cancer 77:2318-2324, 1996
2. Antoniou A, Pharoah PDP, Narod S, et al: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 72:1117-1130, 2003
3. Evans DGR, Bulman M, Young K, et al: Sensitivity of BRCA1/2 mutation testing in 466 breast/ ovarian cancer families. J Med Genet 40:e107, 2003
4. American Society of Clinical Oncology: Statement of the American Society of Clinical Oncology: Genetic testing for cancer susceptibility. J Clin Oncol 14:1730-1736, 1996
5. Eccles DM, Evans DGR, Mackay J: Guidelines for a genetic risk based approach to advising women with a family history of breast cancer. J Med Genet 37:203-209, 2000
6. National Health and Medical Research Council, National Breast Cancer Centre, New South Wales: Advice about familial aspects of breast cancer and ovarian cancer: A guide for health professionals. http:// www.genetics.com.au/ pdf/pubs/boguidelines.pdf
7. Tang NLS, Choy KW, Pang CP, et al: Prevalence of breast cancer predisposition gene mutations in Chinese women and guidelines for genetic testing. Clin Chim Acta 313:179-185, 2001
8. Gilpin CA, Carson N, Hunter AG: A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetics center. Clin Genet 58:299-308, 2000
9. Evans DGR, Eccles DM, Rahman N, et al: A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet 41:474-480, 2004
10. Evans DGR, Lalloo F, Wallace A, et al: An update on the Manchester Scoring System for BRCA1 and BRCA2 testing. J Med Genet 42:e39, 2005
11. Frank TS, Deffenbaugh AM, Reid JE, et al: Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: Analysis of 10,000 individuals. J Clin Oncol 20:1480-1490, 2002
12. Frank TS, Manley SA, Olopade OI, et al: Sequence analysis of BRCA1 and BRCA2. Correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 16:2417-2425, 1998
13. Couch FJ, DeShano ML, Blackwood MA, et al: BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 336:1409-1415, 1997
14. Berry DA, Parmigiani G, Sanchez J, et al: Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst 89:227-238, 1997
15. Parmigiani G, Berry D, Aguilar O: Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62: 145-158, 1998
16. Berry DA, Iversen ES Jr, Gudbjartsson DF, et al: BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 20:2701-2712, 2002
17. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al: The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20:2310-2318, 2002
18. De la Hoya M, Díez O, Pérez-Segura PJ, et al: Pre-test prediction models of BRCA1 or BRCA2 mutation in breast/ovarian families attending familial cancer clinics. J Med Genet 40:503-510, 2003
19. Gross E, Arnold N, Goette J, et al: A comparison of BRCA1 mutation analysis by direct sequencing, SSCP and DHPLC. Hum Genet 105:72-78, 1999
20. Wagner T, Stoppa-Lyonnet D, Fleischmann E, et al: Denaturing-high performance liquid chromatography detects reliably BRCA1 and BRCA2 mutations. Genomics 62:369-376, 1999
21. Garvin AM: A complete protein truncation test for BRCA1 and BRCA2. Eur J Hum Genet 6:226-234, 1998
22. DeLong ER, DeLong DM, Clark-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 44:837-845, 1988
23. Euhus DM, Smith KC, Robinson L, et al: Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst 94:844-851, 2002
24. Lakhani SR: The pathology of familial breast cancer: Morphological aspects. Breast Cancer Res 1:31-35, 1999
25. Breast Cancer Linkage Consortium: Pathology of familial breast cancer: Differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 349:1505-1510, 1997
26. Lakhani SR, Jacquemier J, Sloane JP, et al: Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 90:1138-1145, 1998
27. Osin P, Crook T, Powles T, et al: Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers. Lancet 351:1487, 1998
28. Foulkes WD, Stefansson IM, Chappuis PO, et al: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95:1482-1485, 2003
29. Eisinger F, Nogues C, Guinebretiere J-M, et al: Novel indications for BRCA1 screening using individual clinical and morphological features. Int J Cancer 84:263-267, 1999
30. Cortesi L, Turchetti D, Bertoni C, et al: Comparison between genotype and phenotype identifies a high-risk population carrying BRCA1 mutations. Genes Chromosomes Cancer 27:130-135, 2000